
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
87.600
Open
85.240
VWAP
87.01
Vol
2.86M
Mkt Cap
34.11B
Low
85.240
Amount
249.08M
EV/EBITDA(TTM)
36.50
Total Shares
397.68M
EV
33.26B
EV/OCF(TTM)
34.50
P/S(TTM)
8.44
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.28B
+14.7%
0.689
+53.14%
1.17B
+17.53%
0.566
+25.85%
1.12B
+11.93%
0.448
+4.21%
Estimates Revision
The market is revising Upward the revenue expectations for DexCom, Inc. (DXCM) for FY2025, with the revenue forecasts being adjusted by 0.15% over the past three months. During the same period, the stock price has changed by -1.57%.
Revenue Estimates for FY2025
Revise Upward

+0.15%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+0.3%
In Past 3 Month
Stock Price
Go Down

-1.57%
In Past 3 Month
17 Analyst Rating

13.74% Upside
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 98.93 USD with a low forecast of 85.00 USD and a high forecast of 109.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
1 Hold
0 Sell
Strong Buy

13.74% Upside
Current: 86.980

Low
85.00
Averages
98.93
High
109.00

13.74% Upside
Current: 86.980

Low
85.00
Averages
98.93
High
109.00
Citigroup
Joanne Wuensch
Strong Buy
Maintains
$82 → $102
2025-05-22
Reason
Citigroup
Joanne Wuensch
Price Target
$82 → $102
2025-05-22
Maintains
Strong Buy
Reason
Barclays
Matt Miksic
Hold
Maintains
$90 → $93
2025-05-05
Reason
Barclays
Matt Miksic
Price Target
$90 → $93
2025-05-05
Maintains
Hold
Reason
Barclays raised the firm's price target on DexCom to $93 from $90 and keeps an Equal Weight rating on the shares. The firm made "elatively minor changes" to its model to reflect the company's Q1 results and revised 2025 guidance.
Baird
Jeff Johnson
Buy
Maintains
$115 → $105
2025-05-02
Reason
Baird
Jeff Johnson
Price Target
$115 → $105
2025-05-02
Maintains
Buy
Reason
Baird lowered the firm's price target on DexCom to $105 from $115 and keeps an Outperform rating on the shares. The firm updated its model following mixed Q1 results where momentum was encouraging and the setup is good for second half 2025.
Piper Sandler
Matt O'Brien
Buy
Maintains
$100 → $90
2025-05-02
Reason
Piper Sandler
Matt O'Brien
Price Target
$100 → $90
2025-05-02
Maintains
Buy
Reason
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$103 → $106
2025-05-02
Reason
Canaccord Genuity
William Plovanic
Price Target
$103 → $106
2025-05-02
Maintains
Strong Buy
Reason
Canaccord raised the firm's price target on DexCom to $106 from $103 and keeps a Buy rating on the shares. The firm said they reported a good Q1, beating total and US revenue estimates, while short of OUS estimates but showing strong organic growth OUS.
Mizuho
Anthony Petrone
Buy
Initiates
$85
2025-04-10
Reason
Mizuho
Anthony Petrone
Price Target
$85
2025-04-10
Initiates
Buy
Reason
Mizuho analyst Anthony Petrone initiated coverage of DexCom with an Outperform rating and $85 price target. The firm cites its positive survey data for continued continuous glucose monitoring adoption coupled with "bullish" physician feedback for DexCom's flagship G7 adoption as well as Stelo in the consumer markets for the Outperform rating. Physicians are forecasting the U.S. continued continuous glucose monitoring market to expand 20% over the next two years with the 15-day G7 sensor poised to gain share among various type 2 diabetic populations, the analyst tells investors in a research note. Mizuho has a $100 "bull case" for DexCom shares, which considers faster G7 stabilization and broader Stelo adoption scenarios.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Dexcom Inc (DXCM.O) is 38.95, compared to its 5-year average forward P/E of 102.03. For a more detailed relative valuation and DCF analysis to assess Dexcom Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
102.03
Current PE
38.95
Overvalued PE
147.69
Undervalued PE
56.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
54.70
Current EV/EBITDA
22.52
Overvalued EV/EBITDA
81.51
Undervalued EV/EBITDA
27.90
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
12.73
Current PS
7.04
Overvalued PS
16.80
Undervalued PS
8.65
Financials
Annual
Quarterly
FY2025Q1
YoY :
+12.49%
1.04B
Total Revenue
FY2025Q1
YoY :
+32.25%
133.70M
Operating Profit
FY2025Q1
YoY :
-28.01%
105.40M
Net Income after Tax
FY2025Q1
YoY :
-25.71%
0.26
EPS - Diluted
FY2025Q1
YoY :
-36.44%
96.80M
Free Cash Flow
FY2025Q1
YoY :
-6.82%
56.85
Gross Profit Margin - %
FY2025Q1
YoY :
-36.04%
10.17
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
6.4M
USD
7
3-6
Months
3.8M
USD
9
6-9
Months
202.6K
USD
4
0-12
Months
1.3M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 111.5% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
147.1K
Volume
5
6-9
Months
0.0
Volume
0
0-12
Months
3.1M
Volume
12
Bought
0-3
0
0.0
Volume
Months
3-6
12
2.0M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
16
925.7K
Volume
Months
Congress Trading
Congress areBuying! The buying amount has increased130.77%over the last month.
Sold
0-3
Months
81.0K
USD
4
3-6
Months
150.0K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
107.5K
USD
Months
3-6
1
8.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
6.4M
USD
7
3-6
Months
3.8M
USD
9
6-9
Months
202.6K
USD
4
0-12
Months
1.3M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DXCM News & Events
Events Timeline
2025-05-02 (ET)
2025-05-02
09:55:01
Early notable gainers among liquid option names on May 2nd

2025-05-01 (ET)
2025-05-01
16:05:04
DexCom announce $750M share repurchase program

2025-05-01
16:04:28
DexCom reports Q1 adjusted EPS 32c, consensus 33c

Sign Up For More Events
Sign Up For More Events
News
3.0
05-19NASDAQ.COMValidea Detailed Fundamental Analysis - DXCM
9.0
05-19BenzingaThe End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
6.5
05-19NASDAQ.COMQQQ's Holdings Imply 10% Gain Potential
Sign Up For More News
People Also Watch

GIS
General Mills Inc
53.370
USD
-1.40%

TTWO
Take-Two Interactive Software Inc
228.330
USD
+0.91%

WTW
Willis Towers Watson PLC
311.010
USD
-0.52%

MTB
M&T Bank Corp
181.440
USD
-1.46%

TPL
Texas Pacific Land Corp
1219.540
USD
-1.93%

ROK
Rockwell Automation Inc
312.390
USD
-0.22%

DD
Dupont De Nemours Inc
68.090
USD
-1.70%

LVS
Las Vegas Sands Corp
40.610
USD
-2.47%

EFX
Equifax Inc
262.140
USD
+1.45%

HIG
Hartford Financial Services Group Inc
129.220
USD
-1.34%
FAQ

What is Dexcom Inc (DXCM) stock price today?
The current price of DXCM is 86.98 USD — it has increased 1.93 % in the last trading day.

What is Dexcom Inc (DXCM)'s business?

What is the price predicton of DXCM Stock?

What is Dexcom Inc (DXCM)'s revenue for the last quarter?

What is Dexcom Inc (DXCM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Dexcom Inc (DXCM)'s fundamentals?

How many employees does Dexcom Inc (DXCM). have?
